Tower Research Capital LLC TRC Purchases 6,504 Shares of Humacyte, Inc. (NASDAQ:HUMA)

Tower Research Capital LLC TRC boosted its position in shares of Humacyte, Inc. (NASDAQ:HUMA) by 261.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,989 shares of the company’s stock after purchasing an additional 6,504 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Humacyte were worth $26,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Whittier Trust Co. of Nevada Inc. purchased a new stake in Humacyte in the fourth quarter worth about $28,000. Victory Capital Management Inc. bought a new position in shares of Humacyte during the fourth quarter valued at approximately $29,000. SG Americas Securities LLC purchased a new position in Humacyte during the third quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. raised its stake in Humacyte by 350.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,986 shares of the company’s stock worth $34,000 after buying an additional 9,325 shares in the last quarter. Finally, Kovitz Investment Group Partners LLC bought a new position in Humacyte in the fourth quarter worth approximately $35,000. 44.71% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HUMA. Benchmark reiterated a “buy” rating and issued a $15.00 price target on shares of Humacyte in a report on Monday, March 25th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $7.00 target price on shares of Humacyte in a research note on Monday, April 1st. Finally, Piper Sandler reissued a “neutral” rating and set a $4.00 price target on shares of Humacyte in a research report on Tuesday, March 26th.

Humacyte Stock Up 0.2 %

Shares of HUMA traded up $0.01 during midday trading on Friday, hitting $4.41. 803,493 shares of the company’s stock traded hands, compared to its average volume of 1,704,662. The company has a current ratio of 4.52, a quick ratio of 4.52 and a debt-to-equity ratio of 1.20. The stock has a market capitalization of $525.14 million, a price-to-earnings ratio of -4.12 and a beta of 1.27. Humacyte, Inc. has a 1 year low of $1.96 and a 1 year high of $5.60. The firm’s fifty day moving average is $3.48 and its 200-day moving average is $3.07.

Humacyte (NASDAQ:HUMA) last released its quarterly earnings results on Friday, March 22nd. The company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. During the same period in the previous year, the firm earned ($0.21) earnings per share. As a group, sell-side analysts anticipate that Humacyte, Inc. will post -0.9 earnings per share for the current year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.